Article info

CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling

Authors

  1. Correspondence to Professor Patrick Hwu; Patrick.Hwu{at}moffitt.org
View Full Text

Citation

Fix SM, Forget M, Sakellariou-Thompson D, et al
CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling

Publication history

  • Accepted June 9, 2022
  • First published July 26, 2022.
Online issue publication 
July 26, 2022
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.